ACORDA THERAPEUTICS INC Form 8-K July 12, 2006

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

### FORM 8-K

#### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

July 12, 2006

# Acorda Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware000-5051313-3831168(State or other jurisdiction of incorporation)(Commission (I.R.S. Employer File Number)(Identification No.)

15 Skyline Drive, Hawthorne, NY
(Address of principal executive offices)

10532
(Zip Code)


Registrant s telephone number, including area code: (914) 347-7400

#### Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))



#### Item 7.01. Regulation FD Disclosure.

The Registrant is updating the time period in which it expects to report results from its Phase 3 clinical trial in Fampridine-SR, the Registrant s lead product candidate, for improvement of walking ability in people with multiple sclerosis. The Registrant now expects to report results from this clinical trial in late September or October of this year.

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Acorda Therapeutics, Inc.

July 12, 2006 By: /s/ Ron Cohen

Name: Ron Cohen

Title: President and Chief Executive Officer